Rapport Proposes Common Stock and Convertible Note Offerings
Rapport Therapeutics proposed public offerings of common stock and convertible notes, alongside a concurrent private placement.
Story updates
08:34:17 PM UTC
SquawkNews
Rapport Therapeutics commenced underwritten offerings of $200M common stock and $150M convertible notes due 2032, plus a potential 30-day overallotment and a concurrent private placement at the stock offer price, subject to conditions.Material DetailsContext by AI AnalystThis is a capital raise to…
08:36:59 PM UTC
SquawkNews
RAPPORT THERAPEUTICS - COMMENCES $200 MLN COMMON STOCK AND $150 MLN CONVERTIBLE NOTES OFFERINGS DUE
08:59:12 PM UTC
SquawkNews
Rapport Therapeutics launches $150 million convertible senior notes offering Rapport Therapeutic
BOSTON and SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. NASDAQ:RAPP (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorder…